Analysts Set Globe Life Inc. (NYSE:GL) PT at $191.67

Posted by Stanley Muller on Aug 30th, 2026

Shares of Globe Life Inc. (NYSE:GL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $191.6667.

A number of equities research analysts have recently issued reports on the stock. Jefferies Financial Group upped their price objective on shares of Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a research note on Friday, July 10th. Morgan Stanley lifted their target price on shares of Globe Life from $181.00 to $208.00 and gave the stock an “overweight” rating in a research report on Monday, July 6th. Keefe, Bruyette & Woods decreased their target price on shares of Globe Life from $192.00 to $190.00 and set an “outperform” rating on the stock in a research report on Friday, July 24th. Weiss Ratings downgraded shares of Globe Life from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, July 20th. Finally, TD Cowen upped their price target on shares of Globe Life from $215.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd.

Get Our Latest Report on GL

Globe Life Stock Performance

NYSE:GL opened at $173.41 on Friday. The business has a 50 day moving average of $178.77 and a 200 day moving average of $159.53. The company has a market capitalization of $13.33 billion, a price-to-earnings ratio of 11.51 and a beta of 0.48. Globe Life has a 1-year low of $127.85 and a 1-year high of $191.55. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.07 and a quick ratio of 0.07.

Globe Life (NYSE:GL – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $3.61 EPS for the quarter, missing analysts’ consensus estimates of $3.67 by ($0.06). The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.59 billion. Globe Life had a net margin of 19.58% and a return on equity of 20.52%. The firm’s revenue was up 8.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.05 earnings per share. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. On average, sell-side analysts predict that Globe Life will post 15.71 earnings per share for the current fiscal year.

Globe Life announced that its board has authorized a share repurchase plan on Monday, August 10th that authorizes the company to repurchase $2.50 billion in shares. This repurchase authorization authorizes the company to buy up to 17.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Globe Life Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Monday, October 5th will be issued a $0.33 dividend. The ex-dividend date is Monday, October 5th. This represents a $1.32 annualized dividend and a dividend yield of 0.8%. Globe Life’s payout ratio is currently 8.76%.

Insider Buying and Selling

In related news, CEO James Matthew Darden sold 50,000 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $182.43, for a total transaction of $9,121,500.00. Following the completion of the sale, the chief executive officer directly owned 58,451 shares in the company, valued at $10,663,215.93. This represents a 46.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Thomas Peter Kalmbach sold 21,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $180.06, for a total value of $3,781,260.00. Following the transaction, the chief financial officer owned 50,568 shares in the company, valued at approximately $9,105,274.08. The trade was a 29.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,908 shares of company stock worth $27,239,981 in the last 90 days. 2.11% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Asset Management Ltd. purchased a new stake in Globe Life in the fourth quarter worth $2,073,000. Northwestern Mutual Wealth Management Co. lifted its position in Globe Life by 34,786.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 881,919 shares of the company’s stock valued at $123,345,000 after buying an additional 879,391 shares during the period. Strs Ohio lifted its position in Globe Life by 213.7% during the fourth quarter. Strs Ohio now owns 21,907 shares of the company’s stock valued at $3,064,000 after buying an additional 14,924 shares during the period. Vanguard Group Inc. lifted its position in Globe Life by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 10,090,885 shares of the company’s stock valued at $1,411,311,000 after buying an additional 86,349 shares during the period. Finally, Handelsbanken Fonder AB boosted its holdings in shares of Globe Life by 23.1% during the 4th quarter. Handelsbanken Fonder AB now owns 75,235 shares of the company’s stock valued at $10,522,000 after buying an additional 14,135 shares in the last quarter. Institutional investors own 81.61% of the company’s stock.

Globe Life Company Profile

(Get Free Report)

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.